24 May 2013
Keywords: access, pharmaceuticals, start, phase, ii, trials, topical
Article | 12 November 1998
Access Pharmaceuticals will shortly start Phase II trials of itstopical acne drug ResiDerm A, consisting of clindamycin formulated using
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 June 1998
23 May 2013
© 2013 thepharmaletter.com